Letrozole

Generic Name: Letrozole

Brand Names: Femara, Kisqali Femara Co-pack

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₁N_₅

CAS Number: 112809-51-5

Unique Ingredient Identifier: 7LKK855W8I

Background: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication: Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.

Associated Conditions: Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer

Associated Therapies: -

Clinical Trials

Combined Letrozole and Clomid in Women With Infertility and PCOS

Phase 4

Completed

Conditions: Polycystic Ovary Syndrome
Infertility

Interventions: Drug: Letrozole
Drug: Clomiphene

First Posted Date: 2016-06-16

Last Posted Date: 2019-09-27

Lead Sponsor: Rachel Mejia

Target Recruit Count: 70

Registration Number: NCT02802865

Locations: 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Oral Vinorelbine
Drug: Letrozole

First Posted Date: 2016-06-16

Last Posted Date: 2018-09-20

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 60

Registration Number: NCT02802748

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸
Hospital de León, León, Spain

and more 7 locations

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Fulvestrant
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Drug: Palbociclib
Biological: Pembrolizumab

First Posted Date: 2016-05-20

Last Posted Date: 2024-10-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 47

Registration Number: NCT02778685

Locations: 🇺🇸
City of Hope Corona, Corona, California, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States

and more 4 locations

Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer

Not Applicable

Conditions: Female Infertility Due to Nonimplantation of Ovum

Interventions: Drug: Letrozole
Drug: clomiphene
Drug: HMG

First Posted Date: 2016-05-18

Last Posted Date: 2017-06-23

Lead Sponsor: Navy General Hospital, Beijing

Target Recruit Count: 100

Registration Number: NCT02775877

Locations: 🇨🇳
Department of Obstetrics and Gynecology, Navy General Hospital., Beijing, Beijing, China

Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

Conditions: Breast Cancer

Interventions: Drug: Exemestane
Drug: Letrozole
Drug: Anastrozole

First Posted Date: 2016-05-06

Last Posted Date: 2019-05-13

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT02765373

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Drug: Tamoxifen
Drug: Endocrine Therapy
Drug: Palbociclib

First Posted Date: 2016-05-06

Last Posted Date: 2024-03-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 195

Registration Number: NCT02764541

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Dana-Farber at St. Elizabeth's Medical Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 8 locations

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Abemaciclib
Drug: Anastrozole
Drug: Fulvestrant
Drug: Letrozole

First Posted Date: 2016-05-05

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 463

Registration Number: NCT02763566

Locations: 🇧🇷
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil
🇨🇳
Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China
🇨🇳
Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China

and more 42 locations